New and Investigational Agents for Irritable Bowel Syndrome

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Irritable bowel syndrome (IBS) affects about 15 % of the US population and results in significant morbidity and health care costs. There remains a significant unmet need for effective treatments particularly for the pain component of IBS and other functional gastrointestinal disorders (FGIDs). Progress made in our understanding of pathophysiological mechanisms such as the role of altered bile acid metabolism, neurohormonal regulation, immune dysfunction, the epithelial barrier and secretory properties of the gut has led to advancements in therapeutic armamentarium for IBS. This review discusses the new drugs for constipation and diarrhea-predominant IBS subtypes that have been tested or have been under investigation over the last 3–4 years. Overall, there is a promising pipeline of investigational drugs for the future treatment of IBS and related FGIDs.

Original languageEnglish (US)
Article number46
JournalCurrent gastroenterology reports
Issue number12
StatePublished - Dec 1 2015


  • Constipation
  • Diarrhea
  • Drugs
  • Functional gastrointestinal disorders
  • Pain
  • Treatment

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'New and Investigational Agents for Irritable Bowel Syndrome'. Together they form a unique fingerprint.

Cite this